Abbott Q2 adjusted EPS $1.31; raises FY2026 EPS guidance to $5.45-$5.60

ABBOTT LABORATORIES

Q2 reported sales $12.6B (+13.0% reported, +4.8% comparable); GAAP EPS $0.53, adjusted EPS $1.31.
Full-year 2026 adjusted EPS guidance raised to $5.45-$5.60 from $5.38-$5.58; comparable sales growth reaffirmed at 6.5%-7.5%.
Medical Devices comparable sales +8.4%; Diabetes Care CGM comparable sales +9.5%.
Returned $2.1B to shareholders in Q2 via dividends and share repurchases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.